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Introduction: Acute renal failure (ARF) requiring renal replacement therapy (RRT) occurs frequently in ICU patients
and significantly affects mortality rates. Previously, few large clinical trials investigated the impact of RRT modalities
on patient outcomes. Here we investigated the effect of two major RRT strategies (intermittent hemodialysis (IHD)
and continuous veno-venous hemofiltration (CVVH)) on mortality and renal-related outcome measures.
Methods: This single-center prospective randomized controlled trial (“CONVINT”) included 252 critically ill patients
(159 male; mean age, 61.5 ± 13.9 years; Acute Physiology and Chronic Health Evaluation (APACHE) II score, 28.6 ± 8.8)
with dialysis-dependent ARF treated in the ICUs of a tertiary care academic center. Patients were randomized to receive
either daily IHD or CVVH. The primary outcome measure was survival at 14 days after the end of RRT. Secondary
outcome measures included 30-day-, intensive care unit-, and intrahospital mortality, as well as course of disease
severity/biomarkers and need for organ-support therapy.
Results: At baseline, no differences in disease severity, distributions of age and gender, or suspected reasons for
acute renal failure were observed. Survival rates at 14 days after RRT were 39.5% (IHD) versus 43.9% (CVVH)
(odds ratio (OR), 0.84; 95% confidence interval (CI), 0.49 to 1.41; P = 0.50). 14-day-, 30-day, and all-cause intrahospital
mortality rates were not different between the two groups (all P > 0.5). No differences were observed in days on RRT,
vasopressor days, days on ventilator, or ICU-/intrahospital length of stay.
Conclusions: In a monocentric RCT, we observed no statistically significant differences between the investigated
treatment modalities regarding mortality, renal-related outcome measures, or survival at 14 days after RRT. Our findings
add to mounting data demonstrating that intermittent and continuous RRTs may be considered equivalent approaches
for critically ill patients with dialysis-dependent acute renal failure.
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Acute renal failure (ARF) requiring intermittent or con-
tinuous renal replacement therapy (RRT) significantly af-
fects morbidity and mortality of critically ill patients and
constitutes a substantial health care burden [1]. This re-
mains to be the case despite manifold improvements in
RRT techniques and after substantial advances in sup-
portive ICU care. Importantly, development of ARF con-
stitutes an independent risk factor for death in the ICU,
and data indicate that early induction of RRT signifi-
cantly improves the prognosis of affected patients [1-4].
Continuous RRT (CRRT) is widely used in ICUs and is
often viewed as the preferable approach in critically ill
ARF patients. It remains, however, unclear whether the
choice of initial RRT modality may affect patient out-
comes, as only few prospective randomized controlled
trials (RCTs) have directly compared the different ap-
proaches [5-10]. Often these studies were, however, ei-
ther small and/or had methodologic or randomization
problems. In addition, heterogeneous patient cohorts
were included (surgical/medical) and different CRRT
modalities (convective, diffusive, or both) applied. Only
two larger multicenter RCTs directly compared IHD and
CVVHD [10] or IHD and CVVH [7]. On the whole,
meta-analysis of available data did not demonstrate a gen-
eral survival benefit for either strategy [3,11-15]. Even
fewer data are available regarding end points such as time
to hospital/ICU death or discharge, survival at 14 days
after RRT, or specific renal-related outcome measures.
To identify an RRT option of choice would potentially
have a major impact on clinical procedures. This might
be of particular importance in sepsis-induced renal in-
jury [16] and might also affect treatment costs [17]. We
therefore embarked on a single-center prospective ran-
domized controlled trial (“CONVINT”) that set out to
elucidate further the potential impact of initial choice of
RRT modality by studying a cohort of 252 critically ill
patients with ARF in medical ICU of a tertiary care aca-
demic center.
Materials and methods
Design, study patients, and inclusion/exclusion criteria
Patients with ARF requiring RRT treated at the medical in-
tensive care units (ICUs) of the Charité University Hospital,
Campus Virchow-Klinikum, Department of Nephrology
and Medical Intensive Care, Berlin, Germany, were in-
cluded in this randomized controlled trial (CONtinu-
ous Vs. INTermittent RRT on the outcome of critically
ill patients with ARF trial; CONVINT). CONVINT
was performed from January 2002 until October 2007.
A single-center prospective randomized controlled open-
label trial design applied.
During the recruitment period, adult (>18 years) pa-
tients with ARF requiring RRT were eligible for inclusionin CONVINT. Need for RRT was defined as presence of
at least one of the following criteria: (a) clinical symptoms
of uremia (that is, gastrointestinal symptoms: (for ex-
ample, nausea, vomiting, diarrhea not explained otherwise;
or neurologic symptoms: mental confusion, severe weak-
ness, seizures/coma not explained otherwise; or evidence
of pericardial effusion); (b) persisting oliguria (urinary ex-
cretion rate <0.5 ml/kg/min for >12 hours), or anuria (an-
uria for >12 hours or <0.3 ml/kg/h for >24 hours), despite
adequate fluid management; (c) fluid overload not respond-
ing to diuretic treatment; (d) blood urea nitrogen (BUN)
levels >100 mg/dl or creatinine clearance <0.1 ml/ kg of
body weight/min; (e) severe metabolic acidosis (pH <7.2)
not responding to conventional treatment; and (f) hyperka-
lemia not responding to conservative treatment.
Patients were excluded when any of the following cri-
teria were met: (a) preexisting chronic renal failure with
serum creatinine >3 mg/dl or patients receiving chronic
dialysis; (b) kidney-transplant recipients; (c) patients not
requiring ICU treatment; (d) denial of written informed
consent (patient, legal representative, or legal proxy).
The study was approved by the local Ethics Committee
(Ethikkommission der Charité-Universitätsmedizin Berlin)
and was designed in adherence to the Declaration of
Helsinki. Informed consent to participate in the trial was
obtained from the patient or legal representative. In case a
patient was unable to give informed consent and no legal
representative was available, the Ethics Committee ap-
proval permitted immediate inclusion of the patient in the
trial and to obtain informed consent subsequently, that is,
as soon as a legal representative (next of kin without for-
mal rights of representation not sufficient) was installed
or the patient regained ability to give informed consent.
Data of patients who died before written informed con-
sent was obtained remained in the evaluation. Before
randomization, next of kin were always asked if they
agreed to including the patient in the study and using the
data for future publication. If they declined, or only
expressed concerns regarding potential objections the pa-
tient himself might have against study participation/publi-
cation of data, this patient was not included in the first
place.
Randomization procedure and treatment protocol
After assessment of inclusion and exclusion criteria, pa-
tients were allocated to the respective study groups
(group 1, IHD; group 2, CVVH) at study day 0 (day of
randomization; 1). To assure concealment of allocation,
an independent external telephone (computer-based)
randomization procedure provided by the Department
of Biometry and Medical Documentation, University of
Ulm, Ulm, Germany, was used (permutated blocks of four).
IHD (AK100/AK200; Gambro, Lund, Sweden) was
performed by using polysulfone synthetic membranes.
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of hemodialysis at a blood flow of 200 to 250 ml/min.
A dialysate flow at 500 ml/min, volumetric UF-control,
water purified by reverse osmosis, and bicarbonate di-
alysate was used. Postdilutional CVVH (BM11/BM14;
Baxter Medical, Deerfield, IL, USA, or Multifiltrate,
Fresenius Medical Care, Bad Homburg, Germany) was
applied 24 hours daily by using a polysulfone synthetic
membrane, blood flow of 200 ml/min, prescribed fil-
tration rate of 35 ml/ kg of body weight/hour, by using
bicarbonate-buffered substitution fluids. General treat-
ment target in both groups was absence of any criteria
for acute RRT and a target-time-averaged serum urea
of 100 to 150 mg/dl every 72 hours (mean pre + post +
pre in IHD; not intended as an outcome measure).
CVVH membranes were exchanged every 24 hours in
patients with severe sepsis/septic shock. In all other
patients, membranes were exchanged every 48 hours.
As defined in the study protocol, patients in both study
groups were allowed to be switched to the respective other
RRT modality in cases of significant medical reasons (that
is, either in cases of severe RRT-modality-associated com-
plications or whenever the other modality should not be
withheld for significant medical reasons). In such cases,
switching of the respective RRT modality was performed
by the attending ICU physician. Typical reasons for
switching of RRT modality were as follows IHD to
CVVH: continuous severe hypotension with require-
ment of advanced inotropic support or impossibility of
maintaining fluid homeostasis. CVVH to IHD: patient
mobilization, impossibility of maintaining electrolyte/
acid base homeostasis, impossibility of delivering an
adequate dialysis dose, impossibility of performing
CVVH without anticoagulation in patients with bleed-
ing complications/repeated filter clotting. Number of
changes in RRT modality and respective reasons were
recorded.
Clinical and laboratory follow-up of study patients, outcome
measures
Baseline demographics (including hospital/ICU admis-
sion day), baseline laboratory data (including baseline
blood-gas analyses, urinary output), concomitant diagno-
ses, and reasons for ARF were recorded. For assessment
of clinical disease severity over time, the following clin-
ical scoring systems were used: Sepsis-related Organ
Failure Assessment (SOFA) [18], and Therapeutic Inter-
vention Scoring System (TISS)-28 [19]. Acute Physiology
And Chronic Health Evaluation (APACHE) II score [20]
and Simplified Acute Physiology Score (SAPS)-2 [21]
were recorded at baseline. Data on respective RRT treat-
ments, changes in RRT modality, necessity for mechan-
ical ventilation or vasopressor support, routine laboratory
data (daily until study day 10 and at days 15, 21), andoutcome-related data were recorded daily. Patients were
followed up until 14 days after RRT, withdrawal of con-
sent, or death. Follow-up was performed by using elec-
tronic hospital data-management systems or telephone
follow-up.
The primary outcome measure of CONVINT was sur-
vival at 14 days after end of RRT. Secondary outcome
measures included 14-day-, 30-day-, all cause intrahospi-
tal mortality, days until death (on ICU), days in ICU/
hospital, days on RRT/dialysis-free days, total days on
vasopressors/mechanical ventilation, and course of dis-
ease severity (that is, clinical scores).
Statistical analyses
The initial power calculation aimed at inclusion of n = 200
patients per arm (the OR of failure (that is, primary end
point) between the study groups can be given as the prob-
ability (true logOR is between estimated logOR ± 0.45) is
at least 0.95, under the assumption that failure rates of the
therapies may vary within 40% to 80%. No hypothesis of
superiority of one of the methods studied, nor equality be-
tween the methods, was initially anticipated. Thus, estima-
tion of effects was the focal point. CONVINT was
terminated after inclusion of n = 252 patients in October
2007 after substantial treatment-protocol changes due to
replacement of respective RRT equipment provided by the
university hospital (change in contract; machines provided
by different supplier; please also refer to Discussion sec-
tion). Data from two of the 252 included patients were lost
to follow-up and could not be included in the final ana-
lysis. One patient/proxy per study group withdrew con-
sent (data until withdrawal entered the analysis). With a
sample size of 125 patients per group, a precision of log
OR ± 0.50 is achieved.
As defined in the study protocol, the sample for the
statistical analysis consists of the intention-to treat (ITT)
population. Patients were evaluated in the group to
which they had been randomly allocated. An explorative
PP analysis was performed. Subgroup analyses of pa-
tients with need for advanced inotropic support (nor-
epinephrine dose of >0.3 μg/kg/min at any time during
the study interval; overall sample group) was performed
to identify potential outcome differences between the
study groups. Switches from one RRT modality to the
other were evaluated as a secondary end point. Statistical
methods included Student paired and unpaired t test
and χ2 test, as appropriate. Kaplan-Meier survival estimates
were constructed for illustrative purposes. Data were
checked for normal distribution by using the Kolmogorov-
Smirnov test. Results are reported as means ± standard de-
viations (SD), if not indicated otherwise. Significance was
assigned when P < 0.05. Statistical analyses were performed
by using MedCalc 12.0.1 software (MedCalc Software,
Mariakerke, Belgium).
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Baseline demographics and study groups
Data from n = 128 patients (group 1, IHD) and n = 122
(group 2, CVVH) patients were analyzed (Figure 1). At
baseline, no statistically significant differences between
the study groups were noted regarding demographics,
days on ICU until study inclusion, disease severity (as
assessed by APACHE II, SOFA, SAPS-2, and TISS-28
scores), key physiological and hemodynamic indices (ex-
cept diastolic blood pressure), renal function, and acid/
base balance (Table 1). Concomitant illness was re-
corded in both study groups. The number of patients
with advanced vascular disease, congestive heart failure,
chronic obstructive pulmonary disease, and metabolic
disease (including diabetes) was not different between
the two study groups (Table 1). Major reasons for devel-
opment of ARF were severe sepsis/septic shock (both
groups >65% of study patients at baseline) or cardiogenic
shock (please also refer to Table 1). At baseline, >80% of
study patients in both groups required both mechanical
ventilation and vasopressor support (Table 1) and thus
suffered from multiple organ failure. Main underlying
cause for developing severe sepsis/septic shock was
pneumonia (n= 33 patients in group 1 versus n= 25 patients
in group 2, n.s.). Moreover, 22 patients were initially diag-
nosed with Acute Respiratory Distress Syndrome (ARDS)
(group 1, n = 10; group 2, n= 12; P=n.s.). Peritonitis was
present in n = 5 (group 1) versus n= 5 (group 2) patients
(P=n.s.). In addition, n= 9 (group 1) versus n= 8 patients

























Lost to follow-up (missing data) (n=1)
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Allocated to receive IHD (n=129)
(study group 1)
Received allocated intervention (n=129)
Analysed (n=128)
(study group 1, IHD)
Figure 1 Study flow chart.baseline, no difference in vasopressor need or need for
mechanical ventilation was noted (Table 1).
Follow-up of ARF, need for dialysis, and renal-related
outcome measures
The time course of clinical and laboratory data is shown
in Table 2. Time until dialysis, days on RRT, dialysis-free
days (all n.s.; Tables 1 and 3), as well as course of urinary
output, serum creatinine, and serum urea concentrations
were not different between the two groups. No differ-
ences were noted in serum creatinine at hospital dis-
charge or total fluid balance (Table 3). In the IHD group,
the mean blood-flow rate was 222.9 ± 30.4 ml/min, and
mean dialysate flow rate was 491.4 ± 6.23 ml/min. Mean
duration of IHD was 215.4 ± 82.3 min/session. In the
CVVH group, mean applied dose (that is, filtration rate
was 30.9 ± 7.0 ml/kg body weight/hour (88% of prescribed
dose). Mean blood flow rate in the CVVH group was
188.7 ± 29.4 ml/min. Mean daily ultrafiltration rates were
1.24 ± 0.9 kg (IHD group) and 1.25 ± 1.2 kg (CVVH
group) (P = 0.87), respectively (means ± SD are given).
Anticoagulation was used in 72.8% (IHD) and 74.4%
(CVVH) of sessions (unfractionated heparin used in 99.4%
versus 97.8% of sessions, respectively). Hirudine derivates
or citrate/calcium were used in the remaining cases. Mean
dose of unfractionated heparin was 682.8 ± 357 i.U./hour
(IHD group) versus 781.6 ± 497 i.U./hour (CVVH group)
(P = 0.0001).
As defined in the study protocol, patients in both
groups were allowed to cross over to the respectiveeligibility (n=995)
Excluded:
not meeting inclusion criteria,  
declined to participate (n=743)
ized (n=252)
R
Allocated to receive CVVH (n=123)
(study group 2)
Received allocated intervention (n=123)
Lost to follow-up (missing data) (n=1)
Discontinued intervention (denial of consent, n=1)
Analysed (n=122)
(study group 2, CVVH)
Table 1 Baseline demographics/disease severity, and concomitant diseases
iHD group CVVH group P
value(n = 128) (n = 122)
Age (years) 60.8 ± 13.4 62.3 ± 14.5 0.41
Gender (male) 81 (63.3%) 75 (61.5%) 0.97a*
Major category (nr. of patients) Medical 120 (93.8%) 115 (94.3%) 0.95a*
Postsurgery 8 (6.3%) 5 (4.1%) 0.66a
Posttrauma 0 2 (1.6%) 0.46a
Body weight (kg) 82.1 ± 22.8 86.1 ± 25.2 0.28
Temperature (°Celsius) 37.5 ± 1.2 37.5 ± 1.3 0.74
Hemoglobin (mg/dl)/(hematocrit) (%) 10.6 ± 1.7 10.4 ± 1.7 0.30
[31.7 ± 5.8] [31.4 ± 5.4] [0.72]
Serum creatinine (mg/dl) 3.64 ± 2.3 3.57 ± 1.9 0.81
Serum urea (mg/dl) 159.7 ± 86.5 156.7 ± 77.1 0.77
Serum potassium (mM) 4.66 ± 0.8 4.65 ± 0.9 0.91
Baseline blood pH 7.32 ± 0.2 7.32 ± 0.1 0.82
Baseline HCO3
– 22.6 ± 6.8 21.8 ± 5.4 0.34
Urine output (within 24 hours before randomization; ml) 927.1 ± 1318.4 708.5 ± 937.8 0.10
Days in ICU until randomization 1.0 [0–3.0]b 1.0 [0–2.3]b 0.82
Days from ICU admission until start of RRT 1.0 [0–4.0]b 1.0 [0–3.0]b 0.55
Need for mechanical ventilation (at study day 1) 113 (88.3%) 103 (84.4%) 0.88
paO2/FiO2 ratio (in all patients at study day 1) 197.3 ± 107.9 208.7 ± 106.8 0.45
Need for (any) vasopressor (at study day 1) 104 (81.2%) 106 (86.9%) 0.79a*
Key hemodynamic variables (at study day 1) Heart rate (/min) 104.0 ± 26.1 104.7 ± 20.9 0.81
Systolic blood pressure (mm Hg) 111.6 ± 22.5 109.8 ± 19.4 0.51
Diastolic blood pressure (mm Hg) 56.4 ± 11.1 53.0 ± 13.6 0.04
Central venous pressure (cmH2O) 14.7 ± 5.3 14.2 ± 5.41 0.52
Reason for ARF/need for RRT (number of patients) Cardiogenic failure/ shock 26 (20.3%) 20 (16.4%) 0.61a*
Sepsis-induced 85 (66.4%) 85 (69.7%) 0.89*
Hemorrhagic 2 (1.6%) 3 (2.5%) 0.96*
No shock present 7 (5.5%) 5 (4.1%) 0.85*
Obstruction-induced 0 3 (2.5%) 0.24*
Unknown 8 (6.3%) 9 (7.4%) 0.94*
APACHE-II score 28.5 ± 7.9 28.8 ± 9.6 0.79
SAPS-II score 66.1 ± 18.1 63.8 ± 17.6 0.34
SOFA score 13.2 ± 3.9 13.0 ± 4.0 0.66
TISS-28 score 45.0 ± 10.3 47.1 ± 10.2 0.11
Concomitant disease(s) (number of patients; multiple possible) Atherosclerosis/ischemic HF/AMI 59 (46.1%) 61 (50.0%) 0.80*
Congestive heart failure 19 (14.8%) 20 (16.4%) 0.91*
Arterial hypertension 41 (32.0%) 33 (27.1%) 0.61*
Obstructive pulmonary disease 15 (11.7%) 13 (10.7%) 0.97*
Diabetes mellitus 22 (17.2%) 18 (14.7%) 0.78*
Neurologic/psychiatric/post-stroke 27 (21.1%) 29 (23.8%) 0.80*
Malignancy (solid/hematologic) 30/23 17/22 0.15*
(23.4%/17.9%) (13.9%/18.0%) (0.88)*
Pancreatitis 9 (7.0%) 8 (6.5%) 0.91*
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Postresuscitation 5 (3.9%) 10 (8.2%) 0.28*
Posttransplantation 8 (6.3%) 7 (5.7%) 0.92*
Chronic viral infection 6 (4.7%) 4 (3.3%) 0.82*
Data are given as means ± SD, if not indicated otherwise. Independent samples t test, except *a (chi-square), b (median, IQR).
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sons. Switch of RRT modality was decided by the attend-
ing ICU physician in charge. In total, 19.5% patients
randomized to receive IHD (group 1) versus 45.9% pa-
tients randomized to receive CVVH (group 2) were
switched to the respective other modality during the
study period. Time from both randomization and ICU
admission until switch was not different between the
two study groups: days from randomization until switch
4.4 ± 12.0 (group 1) versus 6.2 ± 5.6 (group 2), P = 0.37.
In the IHD group (group 1), switching of modality was
necessary mainly due to reasons related to progressive
hemodynamic instability (that is, advanced inotropic
support) and/or due to significant fluid overload (16%).
In group 2, switching of modality was mostly indi-
cated because of repeated filter clotting (27%), meta-
bolic reasons (for example, progressive lactic acidosis;
18%), bleeding/discontinuation of anticoagulation re-
quired (11%), severe thrombocytopenia (5%), or be-
cause of desired mobilization/clinical improvement of
study patients.
Course of disease severity/organ dysfunction, key
physiological and laboratory indices
Disease severity was assessed over time by using SOFA
and TISS-28 scoring systems, revealing no differences
between the study groups (Table 2). Cumulative cat-
echolamine need and total days on vasopressors were
not different between the two study groups (data not
shown). Key hemodynamic variables (that is, heart rate,
mean arterial pressure, and central venous pressure) did
not differ between the study groups at randomization,
baseline, and during follow-up (Tables 1 and 2). Need
for mechanical ventilation was assessed in both study
groups. Initial need for mechanical ventilation (Table 1),
total days on mechanical ventilation (Table 3), and
paO2/FiO2 (data not shown) did not differ between the
study groups. During follow-up, other physiological vari-
ables including blood pH, urinary output, temperature,
and C-reactive protein were also not different (Table 2).
Survival at 14 days after RRT, 14-day-, 30-day- and all-cause
mortality data
Survival at 14 days after RRT, 14-day-, 30-day- and all-
cause intrahospital mortality rates were not different be-
tween the study groups in both the ITTand PP populations
(all n.s.; survival rates of the ITT population given inTable 3). The univariate OR (for patients in IHD group) for
survival at 14 days after end of RRT was 0.84 (95% CI, 0.49
to 1.41; P = 0.5). OR (for patients in IHD group) for 14-day
mortality was 1.27 (95% CI, 0.76 to −2.12; P = 0.36). Miss-
ing data (survival at 14 days after RRT) in nine (IHD group)
versus eight (CVVH group) patients (that is, 7.0%, n.s.). OR
(IHD group) for 28-day mortality was 1.37 (95% CI, 0.82 to
2.27; P = 0.22). For patients randomized to receive IHD, the
OR for 30-day mortality was 1.32 (95% CI, 0.80 to
2.19; P = 0.27), and for all-cause intrahospital mortality,
1.26 (95% CI, 0.76 to 2.10; P = 0.37). In the CVVH
study group, the survival rate at 14 days after RRT was
4.4% higher, and mortality rates were not significantly
reduced by 5.8% (14-day mortality), 7.9% (28-day mor-
tality), 7.0% (30-day mortality), and 5.7% (all-cause
intrahospital mortality).
To investigate the potential impact of modality switch
on outcome indices, subanalyses were performed com-
paring patients who switched with those who stayed on
the initial therapy, revealing no influence on the primary
outcome measure, 14-day mortality, 30-day mortality, or
all-cause intrahospital mortality (all P = n.s., data not
shown).
Moreover, we investigated whether higher norepineph-
rine need (defined as >0.3 μg/kg/min at any time during
the study interval) was associated with different out-
comes in the respective study groups. It was noted that,
in this subgroup with higher catecholamine need (n = 47
in group 1 versus n = 40 in group 2), survival at 14 days
after RRT (36.2% versus 37.5%; P = 0.9), 14-day-, 30-day-,
and all-cause mortality rates (65.9% versus 60.0%; P =
0.92) were also not different between the study groups. To
illustrate survival characteristics, Kaplan-Meier survival
estimates were constructed for the total study population
(Figure 2) and the subpopulation receiving a higher vaso-
pressor dose (Figure 3).
Discussion
Acute renal failure (ARF) remains an important deter-
minant for patient outcomes and constitutes a particular
burden for healthcare systems worldwide [1]. Here we
investigate the potential impact of two of the major RRT
modalities (that is, IHD and CVVH) on mortality and
renal-related outcome measures in a single-center pro-
spective randomized controlled trial (CONVINT). After
inclusion of 252 patients with ARF requiring RRT, we
observed no statistically significant differences in 14-day,
Table 2 Course of disease severity, physiological, and laboratory indices
Range, units Group Day 1 Day 3 Day 5 Day 7 Day 10 Day 15 Day 21 P value
Day 1 (day 10)
SOFA score - IHD 13.3 13.0 11.5 10.1 7.6 8.3 5.8 n.s. (n.s.)
±3.7 ±5.1 ±4.6 ±5.2 ±5.0 ±4.3 ±0.8
CVVH 13.0 12.2 10.6 9.5 8.2 8.4 4.7
±4.0 ±3.9 ±4.2 ±5.2 ±5.1 ±4.4 ±7.2
TISS-28 score - IHD 45.3 42.0 41.2 37.8 29.9 35.8 37.6 n.s. (n.s.)
±9.5 ±9.1 ±9.7 ±8.0 ±9.0 ±6.1 ±5.5
CVVH 46.8 43.3 39.9 37.3 33.8 40.4 25.3
±10.2 ±8.3 ±9.1 ±12.3 ±10.8 ±7.9 ±17.2
Serum creatinine <1.20 mg/dl IHD 3.68 3.29 3.17 2.82 2.32 2.54 2.70 n.s. (n.s.)
±1.86 ±2.59 ±1.61 ±1.51 ±1.40 ±1.40 ±1.54
CVVH 3.74 2.18 2.31 2.08 1.93 1.85 1.86
±1.88 ±1.19 ±1.36 ±1.40 ±1.34 ±1.42 ±1.52
Serum urea 14-46 mg/dl IHD 164.8 121.5 125.4 124.9 105.9 120.4 117.6 n.s. (n.s.)
±83.4 ±55.8 ±50.0 ±48.9 ±53.9 ±48.9 ±60.4
CVVH 155.7 93.4 105.1 107.5 94.4 100.9 94.4
±70.0 ±44.3 ±53.2 ±48.9 ±48.3 ±53.3 ±65.7
Urinary output (24 hours) >500 ml IHD 922 944 914 1,331 1,714 1,376 3,570 n.s. (n.s.)
±1,299 ±1,464 ±1,415 ±1,624 ±1,338 ±1,508 ±3,614
CVVH 649 823 1,402 1,645 1,567 1,591 1,964
±948 ±1,323 ±1,785 ±1,636 ±1,474 ±2,093 ±757
pH 7.35-7.45 IHD 7.35 7.37 7.38 7.37 7.39 7.36 7.39 n.s. (n.s.)
±0.1 ±0.1 ±0.1 ±0.1 ±0.1 ±0.1 ±0.1
CVVH 7.36 7.37 7.40 7.38 7.37 7.39 7.39
±0.1 ±0.1 ±0.1 ±0.2 ±0.1 ±0.1 ±0.2
Heart rate 80-100 bpm IHD 104.0 93.8 90.9 92.9 86.9 85.5 86.5 n.s. (n.s.)
±26.1 ±23.3 ±20.3 ±17.0 ±16.4 ±19.9 ±12.9
CVVH 105.2 93.6 90.0 87.5 89.7 93.1 96.5
±21.3 ±22.3 ±20.4 ±19.5 ±18.1 ±17.2 ±15.4
Mean arterial pressure 50-80 mm Hg IHD 73.3 76.5 76.9 82.2 78.1 83.3 70.0 n.s. (n.s.)
±16.5 ±17.6 ±15.9 ±16.7 ±17.2 ±11.9 ±15.1
CVVH 72.0 76.2 76.6 77.7 81.2 75.5 75.3
±14.1 ±13.8 ±12.7 ±12.4 ±14.9 ±25.9 ±16.5
Central venous pressure 8-12 mm Hg IHD 14.7 12.9 12.2 12.2 11.1 10.7 12.9 n.s. (n.s.)
±5.3 ±4.9 ±3.9 ±4.8 ±3.9 ±3.4 ±2.94
CVVH 14.3 13.6 11.8 10.9 12.3 11.5 11.9
±5.4 ±5.6 ±4.2 ±3.8 ±4.6 ±3.6 3.0
Temperature 36.5°C-37.5°C IHD 37.5 37.4 37.2 37.4 37.2 37.7 37.7 n.s. (n.s.)
±1.48 ±1.03 ±1.3 ±0.65 ±1.6 ±0.67 ±0.7
CVVH 37.5 37.1 37.1 37.1 37.2 37.1 37.7
±1.30 ±1.16 ±0.94 ±0.90 ±0.91 ±1.05 ±1.02
C-reactive protein <0.50 mg/dl IHD 18.0 15.6 10.5 10.5 8.3 7.14 11.7 n.s. (n.s.)
±10.0 ±10.1 ±8.3 ±7.7 ±6.7 ±4.95 ±8.25
CVVH 18.8 15.9 10.1 9.4 10.0 12.6 10.8
±10.3 ±9.5 ±8.55 ±7.2 ±7.1 ±7.5 ±7.6
Last column denotes between-group P value (independent-samples t test) at study days 1 and 10. Means ± SD are given.
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Table 3 Clinical outcome of study patients
iHD group CVVH group P value
(n = 128) (n = 122)
Survival at 14 days after RRT 39.5% 43.9% 0.81a
14-day mortality rate 43.6% 37.8% 0.63a
30-day mortality rate 52.4% 45.4% 0.60a
All-cause intrahospital mortality rate (last contact) 60.3% 54.6% 0.72a
Days until death 15.6 ± 44.5 18.5 ± 48.9 0.71
Days until death on ICU 15.5 ± 45.9 18.4 ± 50.0 0.73
Days until hospital discharge (in survivors) 51.2 ± 47.1 48.7 ± 49.7 0.78
Days in ICU 25.2 ± 40.1 22.3 ± 26.1 0.50
Days in hospital 33.9 ± 49.3 32.4 ± 37.4 0.79
Suspected reason for death (multiple possible) Cardiac failure 31 22 0.42a
Pulmonary failure 39 31 0.59a
Sepsis 56 45 0.55a
CNS 7 6 0.92a
Hemorrhagy 5 4 0.93a
Withdrawal of therapy 4 2 0.74a
Days on RRT 17.2 ± 37.1 13.7 ± 17.9 0.35
Dialysis-free days 4.2 ± 9.6 3.1 ± 9.0 0.38
RRT switch (number of patients) 25 (19.5%) 56 (45.9%) 0.002a
Number of patients on RRT (% of survivors, days
after ICU admission)
At 21 days 20 (32.3%) 20 (29.9%) 0.97a
At 60 days 14 (26.4%) 13 (22.8%) 0.90a
Serum creatinine at hospital discharge/last contact
(in survivors; mg/dl)
2.18 ± 1.8 2.12 ± 1.7 0.85
Total days on vasopressors 4.3 ± 3.7 4.5 ± 3.7 0.75
Cumulative vasopressor dose (g) Epinephrine 0.70 0.64 0.96
Norepinephrine 19.1 18.5 0.30
Dobutamine 150.2 137.9 0.56
Total days on mechanical ventilation 8.1 ± 8.8 7.2 ± 6.5 0.34
Total fluid balance (L) 20.5 ± 23.2 24.9 ± 28.4 0.19
Between-group P values are given. Independent samples t test except a(χ2). Means ± SD.
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measures, or survival at 14 days after RRT. Recent meta-
analyses call for larger RCTs because of limited sample
sizes of previous clinical trials and considerable hetero-
geneity of respective study populations [3,11-15]. Our
data support findings from previous studies that inter-
mittent and continuous RRT (CRRT) modalities may be
considered equivalent approaches in a general popula-
tion of critically ill patients with dialysis-dependent ARF.
Our study population consisted of a cohort of critically
ill medical ICU patients with persisting ARF requiring
RRT, despite adequate hemodynamic status. At study
day 1, the mean APACHE II score in the overall sample
was 30.4 ± 7.1. The majority of patients initially pre-
sented with established multiple organ failure. The
major underlying condition for development of multipleorgan failure at baseline was severe sepsis/septic shock.
Besides requiring renal support, most patients required
mechanical ventilation and vasopressor support also
(please refer to Table 1). This may explain the rather
high mortality rates observed in our trial (Table 3, Figure 2).
In line with previously published larger clinical trials in pa-
tients with ARF, severe sepsis/septic shock due to pneumo-
genic or abdominal sepsis was the major underlying
pathology in our study population.
In CONVINT, we deliberately chose to exclude pa-
tients with preexisting advanced chronic renal failure
(that is, patients with previous serum creatinine values
of >3 mg/dl). Patients in CONVINT received daily IHD
for at least 4 hours. In CVVH-treated patients pre-
scribed “dose” (that is, filtration rate was 35 ml/kg/h
based on the landmark trial by Ronco et al. [22] with a













Mantel-Haenszel logrank p-value 0.358




Figure 2 Kaplan-Meier survival estimates for patients randomized to IHD (full line, n = 128) and CVVH (dotted line, n = 122) are
illustrated (total study population). Mantel-Haenszel log-rank P value, hazard ratio (HR) including 95% CI and χ2 is given.
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ancy is in line with previous publications [23] demon-
strating that the applied dose may differ from the
prescribed dose in critically ill patients. This must be
kept in mind when prescribing CRRT.
Until recently, however, the optimal dose of CRRT in
critically ill patients with ARF was controversial. Data
from two recent large-scale multicenter RCTs now dem-













Figure 3 Kaplan-Meier survival estimates for the subpopulation of pa
vasopressor use defined as >0.3 μg/kg/min at any point in time durin
(dotted line, n = 40) groups are illustrated. Mantel-Haenszel log-rank P vnot further improve the outcome of critically ill patients
with ARF [24,25]. Thus, the filtration rate actually ap-
plied in CONVINT could be considered adequate on the
basis of recent recommendations [26].
As recent guidelines [26] also specifically suggest pref-
erential use of CRRT in hemodynamically unstable pa-
tients, we also investigated the effect of IHD versus
CVVH in the subgroup of patients with relevant vaso-
pressor requirements. In the overall study population,ing randomisation
Mantel-Haenszel logrank p-value 0.907




tients with high vasopressor need (overall sample; high
g the study interval) in the IHD (full line, n = 47) versus CVVH
alue, hazard ratio (HR), including 95% CI and χ2 is given.
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tients with norepinephrine need of >0.3 μg/kg/min were
not different between the two study groups (Figure 3),
however, the number of study patients in this subgroup
was rather small. This finding should therefore not be
used as an argument against the preferential use of
CRRT in hemodynamically compromised individuals. As
recommended by the KDIGO guideline [26], priority
should be given to individualized therapeutic decisions
that are made by ICU specialists or consulting nephrolo-
gists on the basis of the specific clinical and hemodynamic
status of the patient.
A number of limitations of our analysis require discus-
sion. First, the initial power calculation aimed at inclu-
sion of 200 patients per arm. CONVINT was terminated
early after inclusion of 252 patients (63% of the targeted
population). The reason for early trial termination was a
major change in RRT equipment and procedures that
was beyond the investigators’ control. With the ICU
team confronted with new machinery and new treatment
protocols (for instance, automated citrate anticoagula-
tion, preference for HDF instead of HD), it became obvi-
ous that this would introduce an unacceptable bias to
the trial. The investigators therefore decided to termin-
ate the study prematurely.
After termination of the trial, a retrospective explora-
tive analysis was performed to determine whether the
trial might have been able to reach statistical significance
regarding the primary end point if continued as planned.
This was, however, not the case, as the between-group
Pvalue for the primary outcome measure would not have
reached statistical significance in the unlikely event that
survival rates at 14 days after RRT in the 148 remaining
cases had differed between groups by an additional 30%.
However, by definition, we cannot rule out an effect of
underpowering and related beta error on the outcome
measures (including renal outcome measures) after early
trial termination.
Second, switching of RRT modality in cases of signifi-
cant RRT modality-related complications or medical rea-
sons was deliberately allowed in the study protocol. This
was done for safety reasons and was considered inevit-
able in this cohort of critically ill patients. Although the
substantial number of cross-overs could have influenced
our overall findings, differences in both the primary end
point and respective mortality rates in the subgroups of
patients switched/not switched were not observed.
Third, we present data from a single-center RCT, and
the overall trial period was rather long. Thus, the inher-
ent limitations of monocentric trials should be kept in
mind when analyzing the data provided. Nevertheless, as
therapeutic standards of care were unchanged during
the trial period, we believe that the total study interval
should be a minor limitation of our analysis.Fourth, we defined a previous serum creatinine value
of >3 mg/dl as an exclusion criterion to exclude patients
with advanced chronic renal failure. Conversely, patients
with moderate to advanced chronic renal insufficiency
could be included in the study and might have influ-
enced our data.
Conclusions
In conclusion, after recruitment of 252 patients with
dialysis-dependent ARF to a prospective single-center
randomized controlled trial, we observed no statistically
significant differences regarding 14-day-, 30-day-, all-
cause intrahospital mortality, renal-related outcome
measures, or survival at 14 days after RRT. Moreover, no
significant effect of the RRT modality on the percentage
of surviving patients still requiring RRT at days 21 or 60
was observed. Our data lend further support to the view
that intermittent and continuous RRT may be consid-
ered equivalent approaches for a general population of
critically ill patients with dialysis-dependent ARF treated
in a medical ICU.
Key messages
 In critically ill patients with dialysis-dependent ARF,
statistically significant differences regarding mortality
rates, renal-related outcome measures, or the rate of
surviving patients at 14 days after end of RRT were
not observed between patients randomized to receive
either daily iHD or CVVH.
 In the subgroup of patients with higher
catecholamine need, survival at 14 days after RRT,
14-day, 30-day, and all-cause mortality rates were
also not different between the two RRT modalities
(that is, daily iHD versus CVVH).
 Our data support the view that intermittent and
continuous RRT may be considered equivalent
approaches for a general population of critically ill
patients with dialysis-dependent ARF treated in a
medical ICU.
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